Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2016 / Dec / How to HER2
Oncology Oncology Precision medicine Screening and monitoring Regulation and standards Genetics and epigenetics Omics Molecular Pathology

How to HER2

CAP, ASCP, and ASCO issue joint HER2 guidelines for GEA patients

By William Aryitey 12/15/2016 1 min read

Share

Gastroesophageal adenocarcinoma (GEA) is consistently in the top five cancers globally, with over 43,000 cancer cases this year in the United States alone, and yet, in spite of this high prevalence, it still goes largely undiagnosed until the late stages. HER2-targeted therapies, best known for their role in breast cancer treatment, can offer some hope – but delayed diagnosis limits their effectiveness (1). In the absence of any clear guidance, and the insufficiency of HER2 testing guidance for breast cancer in this set of patients, the College of American Pathologists, the American Society for Clinical Pathology, and the American Society of Clinical Oncology teamed up to issue joint evidence-based guidelines for HER2 testing in GEA (1).

Table 1. CAP/ASCP/ASCO guidelines to pathologists for HER2 testing in GEA patients.

The expert panel created a list of 11 recommendations to ensure optimal HER2 testing – three specifically aimed at clinicians and eight at pathologists. Those for pathologists are listed in Table 1. According to guideline Co-chair, Mary Kay Washington, a pathologist at Vanderbilt University Medical Center, “The pathologist can use the guidelines to decide which specimens might be best suited for testing,” adding, “it also provides a step-by-step procedure for the order in which the tests should be performed.” Given the high prevalence of the condition, Washington believes “this guideline has the potential to impact a large number of patients.”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. AN Bartley et al., “HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathologists, and American Society of Clinical Oncology”, Arch Pathol Lab Med, 140, 1345-1363 (2016). PMID: 27841667.

About the Author(s)

William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

More Articles by William Aryitey

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.